Clinical trials: MSA
MSA - Multiple System Atrophy, MSA
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism…
- Trial name
- NCT07465198
- Testing
- MSCs
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Biocells Medical
Multiple System Atrophy (MSA), Parkinson's Disease (PD)
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.
- Trial name
- NCT07604116
- Testing
- SST001
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Synusight Biotech (Shanghai) Co., Ltd.
Symptomatic Neurogenic Orthostatic Hypotension
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
- Trial name
- SEQUOIA (NCT03750552)
- Testing
- ampreloxetine
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 195 people
- Sponsor
- Theravance Biopharma
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Gastroesophageal Reflux
RETHINK REFLUX Registry
The RETHINK REFLUX Registry is a post-market prospective, multi-center, observation, single arm, long-term safety surveillance registry of subjects implanted with the LINX device.
- Trial name
- NCT04253392
- Testing
- LINX Reflux Management System
- Where
- 28 sites in United States, Austria and 4 more
- Volunteers
- 500 people
- Sponsor
- Ethicon Endo-Surgery
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Multiple System Atrophy
Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy
The purpose of conducting phase 1 trial is to evaluate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells(CS10BR05) in subjects with Multiple System Atrophy.
- Trial name
- NCT03265444
- Testing
- CS10BR05
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Corestemchemon, Inc.
Progressive Supranuclear Palsy, Multiple System Atrophy
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20 subjects will be treated with placebo and NBMI 300 mg in a cross-over design.
- Trial name
- EMERA006 (NCT04184063)
- Testing
- NBMI
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- EmeraMed
Multiple System Atrophy (MSA), Healthy Adult
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of [¹⁸F]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls…
- Conditions
- Multiple System Atrophy (MSA), Healthy Adult, Parkinson Disease
- Trial name
- MODAG-009-P1-0 (NCT07640555)
- Testing
- [¹⁸F]MODAG-009 PET imaging
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Multiple System Atrophy
Study of BHV-3241 in Participants With Multiple System Atrophy
The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy
- Trial name
- M-STAR (NCT03952806)
- Testing
- Verdiperstat
- Where
- 48 sites in United States, Austria and 4 more
- Volunteers
- 421 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Multiple System Atrophy, Neurodegenerative Diseases
Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
This is a randomized controlled parallel Group phase I study to investigate the safety and immunological/ therapeutic activity of two new vaccines, AFFITOPE® PD01A and AFFITOPE® PD03A, given to patients with early Multiple System…
- Trial name
- AFF009 (NCT02270489)
- Testing
- AFFITOPE® PD01A + Adjuvant, AFFITOPE® PD03A + Adjuvant, Adjuvant without active component
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Affiris AG
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Multiple System Atrophy (MSA)
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA.
- Trial name
- NCT05923866
- Testing
- ONO-2808
- Where
- 35 sites in United States, Japan
- Volunteers
- 92 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and…
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
- Trial name
- NCT05699460
- Testing
- This is an observational study.
- Where
- 11 sites in United States, Poland
- Volunteers
- 73 people
- Sponsor
- AskBio Inc
the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)
The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).
A Phase I Study to Assess the Safety, Tolerability and Efficacy of dopaminergic neural progenitor cells (XS411CN cell injection) for the treatment of multiple system atrophy Parkinsonian variant (MSA-P).
- Trial name
- NCT07617012
- Testing
- XS411CN Cell Injection
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH302 (NCT00633880)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 181 people
- Sponsor
- Chelsea Therapeutics
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH303 (NCT00738062)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 103 people
- Sponsor
- Chelsea Therapeutics
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma
Multiple System Atrophy
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
- Trial name
- NCT06868628
- Testing
- Foralumab Nasal
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tiziana Life Sciences LTD